William Blair Reiterates Outperform Rating for Axsome Therapeutics (NASDAQ:AXSM)

William Blair reaffirmed their outperform rating on shares of Axsome Therapeutics (NASDAQ:AXSM - Free Report) in a research note released on Tuesday morning,RTT News reports. William Blair also issued estimates for Axsome Therapeutics' Q1 2025 earnings at ($1.46) EPS, Q2 2025 earnings at ($1.28) EPS, Q3 2025 earnings at ($0.92) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($4.23) EPS, Q1 2026 earnings at ($0.39) EPS, Q2 2026 earnings at $0.22 EPS, Q3 2026 earnings at $0.93 EPS, Q4 2026 earnings at $1.62 EPS, FY2026 earnings at $2.38 EPS and FY2027 earnings at $13.85 EPS.

Several other brokerages have also recently weighed in on AXSM. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $121.00 target price on shares of Axsome Therapeutics in a research note on Thursday, December 12th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $139.00 target price on shares of Axsome Therapeutics in a research note on Wednesday, January 29th. Robert W. Baird upped their target price on Axsome Therapeutics from $112.00 to $116.00 and gave the company an "outperform" rating in a report on Wednesday, November 13th. Wells Fargo & Company upped their target price on Axsome Therapeutics from $140.00 to $160.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on Axsome Therapeutics in a report on Tuesday, February 11th. They set a "buy" rating and a $176.00 target price for the company. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Axsome Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $155.47.

Axsome Therapeutics Stock Performance

Shares of NASDAQ:AXSM traded up $8.65 on Tuesday, hitting $137.75. The company's stock had a trading volume of 1,539,189 shares, compared to its average volume of 1,103,887. The stock's 50-day moving average is $101.29 and its two-hundred day moving average is $94.84. Axsome Therapeutics has a 12 month low of $64.11 and a 12 month high of $139.13. The company has a market capitalization of $6.72 billion, a price-to-earnings ratio of -23.00 and a beta of 1.05. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.37 and a current ratio of 2.11.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The business had revenue of $118.77 million during the quarter, compared to analysts' expectations of $117.83 million. On average, equities research analysts forecast that Axsome Therapeutics will post -2.26 EPS for the current year.

Insider Buying and Selling

In related news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares of the company's stock, valued at approximately $5,529,450.09. This represents a 6.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 22.40% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Pitcairn Co. increased its position in Axsome Therapeutics by 3.4% in the 4th quarter. Pitcairn Co. now owns 4,562 shares of the company's stock worth $386,000 after purchasing an additional 148 shares during the last quarter. Meridian Wealth Management LLC increased its position in Axsome Therapeutics by 0.7% in the 4th quarter. Meridian Wealth Management LLC now owns 21,171 shares of the company's stock worth $1,791,000 after purchasing an additional 150 shares during the last quarter. Summit Investment Advisors Inc. increased its position in Axsome Therapeutics by 4.4% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,852 shares of the company's stock worth $326,000 after purchasing an additional 162 shares during the last quarter. Arizona State Retirement System increased its position in Axsome Therapeutics by 1.8% in the 4th quarter. Arizona State Retirement System now owns 9,054 shares of the company's stock worth $766,000 after purchasing an additional 164 shares during the last quarter. Finally, Intrust Bank NA increased its position in Axsome Therapeutics by 6.9% in the 4th quarter. Intrust Bank NA now owns 2,823 shares of the company's stock worth $239,000 after purchasing an additional 183 shares during the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.